文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

晚期慢性肾脏病老年患者接受高剂量氟喹诺酮治疗与严重不良事件的相关性

Association of Higher-Dose Fluoroquinolone Therapy With Serious Adverse Events in Older Adults With Advanced Chronic Kidney Disease.
PubMed 文献 · JAMA Netw Open · 2022-08-01
一句话结论晚期CKD老年患者使用高于推荐剂量的氟喹诺酮,14天内因神经/精神障碍、低血糖或胶原相关事件就诊的复合结局风险显著高于低剂量组。

这项基于加拿大安大略省(2008年1月1日至2020年3月17日)的基于人群的队列研究,纳入11917例66岁及以上、eGFR<30 mL/min/1.73 m²且未透析的晚期CKD氟喹诺酮新使用者,比较高剂量(环丙沙星501-1000 mg/d、左氧氟沙星501-750 mg/d或诺氟沙星401-800 mg/d)与低剂量(环丙沙星500 mg/d、左氧氟沙星250-500 mg/d或诺氟沙星400 mg/d)处方的14天风险。经逆概率治疗加权后,高剂量组主要复合结局(因神经和/或精神障碍、低血糖或胶原相关事件就诊)发生率为1.2%(68/5482),低剂量组为0.9%(47/5516),加权风险比1.45(95%CI 1.01-2.08),加权风险差0.39%(95%CI 0.01%-0.76%)。脓毒症、视网膜脱离、全因住院、全因死亡和心源性猝死风险组间无显著差异。作者认为,晚期CKD老年患者使用高于推荐剂量的氟喹诺酮与复合不良事件风险升高相关,但绝对风险低于2%。

要点

  • 晚期CKD(eGFR<30 mL/min/1.73 m²、未透析)老年患者高剂量氟喹诺酮组14天复合结局(神经/精神障碍、低血糖或胶原相关事件就诊)1.2% vs 低剂量组0.9%,加权RR 1.45(95%CI 1.01-2.08)。
  • 加权风险差0.39%(95%CI 0.01%-0.76%),绝对风险增加幅度小,但置信区间下限接近0。
  • 脓毒症、视网膜脱离或其他肌腱病、全因住院、全因死亡、心源性猝死风险两组无显著差异。
  • 研究定义的高剂量为环丙沙星501-1000 mg/d、左氧氟沙星501-750 mg/d或诺氟沙星401-800 mg/d;低剂量为环丙沙星500 mg/d、左氧氟沙星250-500 mg/d或诺氟沙星400 mg/d。
  • 作者认为晚期CKD老年患者使用高于推荐剂量的氟喹诺酮与复合不良事件风险升高相关,但绝对风险低于2%。

适用人群与场景

  • 加拿大安大略省66岁及以上成人,晚期CKD(eGFR<30 mL/min/1.73 m²)且未接受透析,新开具氟喹诺酮抗生素处方者。
  • 研究基于2008年1月1日至2020年3月17日的关联健康管理数据,数据分析时间为2021年1月1日至4月30日。

诊断标准与关键阈值

  • 晚期CKD定义为eGFR<30 mL/min/1.73 m²且未接受透析。
  • 高剂量氟喹诺酮定义:环丙沙星501-1000 mg/d、左氧氟沙星501-750 mg/d或诺氟沙星401-800 mg/d。
  • 低剂量氟喹诺酮定义:环丙沙星500 mg/d、左氧氟沙星250-500 mg/d或诺氟沙星400 mg/d。

研究设计与关键结果

  • 基于人群的队列研究,纳入11917例患者(中位年龄83岁[IQR 77-89岁];女性7438例[62.4%];中位eGFR 25[IQR 21-28] mL/min/1.73 m²),其中5482例(46.0%)接受高剂量氟喹诺酮,6435例(54.0%)接受低剂量氟喹诺酮。
  • 主要复合结局(因神经和/或精神障碍、低血糖或胶原相关事件就诊)经加权后,高剂量组68/5482例(1.2%)vs 低剂量组47/5516例(0.9%);加权风险比1.45(95%CI 1.01-2.08);加权风险差0.39%(95%CI 0.01%-0.76%)。
  • 脓毒症、视网膜脱离或其他肌腱病、全因住院、全因死亡和心源性猝死风险两组间无显著差异。

证据类型、等级与局限

  • 证据类型:基于人群的队列研究。
  • 采用倾向性评分逆概率治疗加权平衡基线健康状态;加权风险比和风险差分别通过改良泊松回归和二项回归获得。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,晚期CKD老年患者使用高于推荐剂量的氟喹诺酮与因神经和/或精神障碍、低血糖或胶原相关事件就诊的复合结局风险升高相关,但绝对风险低于2%。
  • 研究结果提示,对晚期CKD老年患者处方氟喹诺酮时,高剂量与复合不良事件风险升高相关;脓毒症、视网膜脱离或其他肌腱病、全因住院、全因死亡和心源性猝死风险两组无显著差异。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Population-based data are needed to inform the safe prescribing of fluoroquinolone antibiotics to patients with advanced chronic kidney disease (CKD).

OBJECTIVE: To quantify the 14-day risk of a hospital visit with nervous system and/or psychiatric disorders, hypoglycemia, or a collagen-associated event in patients with advanced CKD newly prescribed a fluoroquinolone at a higher vs a lower dose.

DESIGN, SETTING, AND PARTICIPANTS: This population-based cohort study in Ontario, Canada (January 1, 2008, to March 17, 2020) used linked health care data to identify new users of fluoroquinolone antibiotics. Participants included adults 66 years or older with advanced CKD (an estimated glomerular filtration rate [eGFR] <30 mL/min/1.73 m2 but not receiving dialysis). Data analysis was performed from January 1 to April 30, 2021.

EXPOSURES: A new prescription for a higher-dose fluoroquinolone (ciprofloxacin, 501-1000 mg/d; levofloxacin, 501-750 mg/d; or norfloxacin, 401-800 mg/d) vs a lower-dose fluoroquinolone (ciprofloxacin, 500 mg/d; levofloxacin, 250-500 mg/d; or norfloxacin, 400 mg/d).

MAIN OUTCOMES AND MEASURE: The primary outcome was the 14-day risk of a hospital visit with nervous system and/or psychiatric disorders, hypoglycemia, or a collagen-associated event. Secondary outcomes included a hospital visit with sepsis, retinal detachment or other tendinopathies, all-cause hospitalization, all-cause mortality, and sudden cardiac death. Inverse probability of treatment weighting on the propensity score was used to balance comparison groups on baseline health. Weighted risk ratios and risk differences were obtained using modified Poisson regression and binomial regression, respectively.

RESULTS: Of 11 917 patients (median age, 83 years [IQR, 77-89 years]; 7438 women [62.4%]; median eGFR, 25 [IQR, 21-28] mL/min/1.73 m2) included in the analysis, 5482 (46.0%) received a higher-dose and 6435 (54.0%) received a lower-dose fluoroquinolone. After weighting, the primary composite outcome-a hospital visit with nervous system and/or psychiatric disorders, hypoglycemia, or a collagen-associated event-occurred in 68 of 5482 patients (1.2%) treated with a higher-dose fluoroquinolone and in 47 of 5516 (0.9%) treated with a lower-dose fluoroquinolone (weighted risk ratio, 1.45 [95% CI, 1.01-2.08]; weighted risk difference, 0.39% [95% CI, 0.01%-0.76%]). The risk of sepsis, retinal detachment, all-cause hospitalization, all-cause mortality, and sudden cardiac death did not differ significantly between groups.

CONCLUSIONS AND RELEVANCE: These findings suggest that older patients with advanced CKD who were prescribed a fluoroquinolone at a higher-than-recommended dose were significantly more likely to experience the composite outcome of a hospital visit with nervous system and/or psychiatric disorders, hypoglycemia, or a collagen-associated event, although the absolute risk of these events was less than 2%.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Muanda FT, Sood MM, Weir MA, et al. Association of Higher-Dose Fluoroquinolone Therapy With Serious Adverse Events in Older Adults With Advanced Chronic Kidney Disease. JAMA Netw Open. 2022. PMID: 35917124. doi:10.1001/jamanetworkopen.2022.24892

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。